Loading…
MDWD
MediWound Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP M68830112
$12.66-4.38%Price as of Aug 29, 18:31 UTC · updated once a day, after the close
Key metrics
- Market cap
- $163.44M
- P/E
- —
- Forward P/E
- —
- P/B
- 4.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.07
- ROE
- -72.37%
- Profit margin
- -170.10%
- Revenue growth
- -45.80%
- Beta
- 0.16
- 52-week high
- $20.30
- 52-week low
- $12.52
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -43.8% over 5Y.
today you would have $591.96▼ -40.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $18.46 | $17.80 | $10.17 | $13.49 | |
| P/S | 7.3x | 14.0x | 9.5x | 5.0x | 3.7x |
| P/B | 5.8x | 5.4x | 6.2x | 3.0x | 8.9x |
| EPS | -$2.10 | -$3.03 | -$0.75 | -$3.93 | |
| Profit margin | -107.39% | -140.80% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NYXHNyxoah SA | $1.60 | — | 1.7x | — | -122.68% | $162.94M |
| LFMDLifeMD, Inc. | $3.30 | — | 19.8x | — | -515.90% | $159.06M |
| BNRBurning Rock Biotech Ltd | $15.08 | — | 2.2x | — | -12.82% | $158.99M |
| CLLSCellectis S.A. | $1.56 |
About the company
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
- 121
- Yavne, Israel
Company description provided by Yahoo Finance.